Table 2. Univariate and multivariate analysis of the training cohort.

Variables	Univariate analysis			Multivariate analysis
	OR	95% CI	P value	OR	95% CI	P value
Age, ≥65	0.841	0.453–1.508	0.571
Gender, male	1.430	0.799–2.515	0.220
BMI, ≥25 kg/m2	0.770	0.398–1.418	0.417
Metabolic syndrome	1.926	0.603–5.260	0.226
Alcohol consumption	1.321	0.687–2.443	0.387
Liver cirrhosis	0.783	0.225–2.105	0.660
Fatty liver disease	1.305	0.194–5.368	0.740
IHD stones	2.902	1.240–6.435	0.010	3.464	1.233–9.528	0.016
Clonorchiasis infestation	0.506	0.136–1.802	0.290
Tumor size, ≥5.0 cm	1.075	0.991–1.163	0.074
Tumor location, central	1.817	1.182–2.805	0.007
Tumor number, ≥2	5.678	2.883–11.142	<0.001	5.987	2.643–13.887	<0.001
Vascular invasion	2.096	1.151–3.751	0.014
LN enlargement	12.554	6.463–26.460	<0.001	12.655	6.243–27.947	<0.001
AST	1.002	0.993–1.010	0.704
ALT	1.006	0.997–1.013	0.171
ALP	1.002	1.000–1.004	0.042
Total bilirubin	1.141	0.839–1.503	0.336
Albumin, <3.5	1.691	0.953–2.965	0.069
CRP, ≥1.0	1.419	0.756–2.577	0.261
NLR, ≥2.7	2.106	1.209–3.677	0.008	1.981	1.027–3.850	0.042
CA-19–9, ≥37	1.889	1.086–3.340	0.026

ALP, alkaline phosphatase; ALT, alanine aminotransaminase; AST, aspartate aminotransferase; BMI, body mass index; CA-19-9, carcinohydrate antigen, CI, confidence interval; CRP, C-reactive protein; IHD, intrahepatic duct; LN, lymph node; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio.